主要目标：临床试验每组的无进展生存期(PFS) 次要目标：临床试验每组的至肿瘤进展时间(TTP)；临床试验每组的客观缓解率 (ORR)；临床试验每组的疾病控制率 (DCR)；临床试验每组的总生存期(OS)；根据不良事件的发生率和严重程度评估YIV-906联合索拉非尼组合的安全性和耐受性；临床试验每组中的生活质量 (QoL) 变化；确定YIV-906对于索拉非尼药代动力学（PK）的影响。探索性目标：为了研究YIV-906联合索拉非尼在患者中的生物学效应，为肝癌的早期检测和精确治疗以及预后分析奠定基础，本研究将对一系列生物标志物进行分析，其中包括：AFP、AST、ALT、细胞因子、趋化因子、HBV血清学标志物、HBV病毒载量、循环肿瘤DNA以及血清代谢组学；分析上述可溶性生物标志物结果与临床治疗终点的相关性；分析可溶性生物标志物之间的相关性；比较两组患者体内的肠道和口腔有益和致病菌群组成，包括治疗前和治疗后的对比。

开始日期2021-04-15

申办/合作机构

Yiviva, Inc.初创企业

[+2]

NCT04000737

/ Unknown status临床2期

A Phase II Randomized Placebo-Controlled Study Investigating The Combination Of YIV-906 And Sorafenib (Nexavar®) In HBV (+) Patients With Advanced Hepatocellular Carcinoma

The aim of this study is to compare the efficacy and safety of YIV-906 plus standard-of-care sorafenib versus those of sorafenib alone as a first-line systemic treatment for patients with Hepatitis B (+) associated advanced hepatocellular carcinoma.
YIV-906 (PHY906, KD018) is an immune system modulator. Clinical and preclinical research suggests that YIV-906 could act to enhance the body's immune response to fight cancer and increase the anti-tumor activity of sorafenib and protect and repair the gastrointestinal tract by reducing inflammation and promoting tissue regeneration.
Inspired by a 1,800-year-old traditional medicine still in use today, YIV-906 is a botanical drug candidate, composed of an extract of four herbs and administered in oral capsule form.
The CALM (Combination of YIV-906 and Sorafenib to treat Advanced Liver cancer in a Multi-center study) trial is a multi-regional, randomized, placebo-controlled study.

开始日期2020-01-10

申办/合作机构

Yiviva, Inc.初创企业

NCT02178644

/ Completed临床1期IIT

Pilot Trial of KD018 With Neo-Adjuvant Concurrent Chemo-Radiation Therapy in Patients With Locally Advanced Rectal Cancer

This pilot study focuses on KD018 and will investigate the effect of this agent on reducing the Gastrointestinal (GI) toxicity associated with combined modality therapy of locally-advanced rectal cancer.

开始日期2014-07-01

申办/合作机构

Yale University

100 项与 YIV-906 相关的临床结果

登录后查看更多信息

100 项与 YIV-906 相关的转化医学

登录后查看更多信息

100 项与 YIV-906 相关的专利（医药）

登录后查看更多信息

项与 YIV-906 相关的文献（医药）

2024-06-01·Journal of Gastrointestinal Oncology

A single arm phase 2 clinical trial of YIV-906 with neoadjuvant concurrent chemo-radiation therapy in patients with locally advanced rectal cancer

Article

作者: Cheng, Yung-Chi ; Lacy, Jill ; Higgins, Susan A ; Hochster, Howard ; Lam, Wing ; Zaheer, Wajih ; Stein, Stacey ; Verma, Nipun ; Cecchini, Michael ; Liu, Shwu-Huey ; Johung, Kimberly L ; Kortmansky, Jeremy ; Reddy, Vikram

BackgroundPre-operative chemoradiation for rectal cancer is often associated with severe gastrointestinal (GI) toxicity which can interrupt, delay, and/or lead to termination of treatment. In this study, we evaluated whether the addition of YIV-906, a novel herbal medicine proven to reduce GI toxicity associated with chemotherapy could also reduce GI side effects during standard pre-operative capecitabine and pelvic radiation therapy (RT) in the neoadjuvant setting for the treatment of locally advanced rectal cancer.MethodsThis single arm clinical study enrolled 24 patients between Dec 23, 2014-Sep 17, 2018 at Smilow Cancer Hospital, a comprehensive cancer center at Yale New Haven Hospital. All patients were age ≥18 years, Eastern Cooperative Oncology Group 0-1 and with histologically confirmed T3-T4 and N0-N2, M0 adenocarcinoma of the rectum. Median follow-up was 61.9 months. All patients received concurrent pelvic external beam RT (50.4 Gy in 28 fractions), YIV-906 (taken orally 800 mg twice daily on days 1-4 of RT each week), and oral capecitabine delivered in a neo-adjuvant fashion, followed by definitive surgery. Toxicity was assessed weekly during radiation and until acute symptoms resolved and then at 28 days, 4 months, 7 months and 10 months. Toxicities were graded in accordance with Common Terminology Criteria for Adverse Events (CTCAE) version 4.0.ResultsAt the time of surgery, 4 patients (16.7%) had a complete or near-complete response. At a median follow-up of 61.9 months, the mean overall survival (OS) of our patient cohort was 74.9 months [95% confidence interval (CI): 67.3-82.5]. The estimated 5-year OS was 82.0%. We observed 0% acute grade 4 toxicities, and only two cases of acute grade 3 diarrhea (8.3%).ConclusionsThe addition of YIV-906 to capecitabine based chemoradiation for locally advanced rectal cancer led to reduced rates of GI toxicity compared to historical controls, in particular grade 3 or greater diarrhea. These findings suggest YIV-906 should be evaluated in a randomized clinical trial to further assess potential reductions in the toxicity profile of chemoradiation for GI cancers.

2024-01-01·Integrative Cancer Therapies

Efficiency of Protective Interventions on Irinotecan-Induced Diarrhea: A Systematic Review and Meta-Analysis

Review

作者: Xiong, Xia ; Zhang, Wei ; Wang, Xuan ; Deng, Mingming ; He, Bing ; Wang, Yu ; He, Yanxi ; Liang, Sicheng ; Zhao, Wenjing ; Qi, Xiaoyi ; Wu, Lili

Background: Irinotecan is widely used in the treatment of various solid tumors, but the adverse effects from it, especially diarrhea, limit its use. Several clinical trials of prophylactic treatment of irinotecan-induced diarrhea (IID) have been ongoing, and some of the data are controversial. This encouraged us to conduct a meta-analysis of the effects of interventions on preventing IID. Method: This systematic review was conducted based on the PRISMA statement. We performed literature searches from PubMed, Web of Science, Embase, and Cochrane Library. The number registered in PROSPERO is CRD42022368633. After searching 1034 articles in the database and references, 8 studies were included in this meta-analysis. Result: The RR of high-grade diarrhea and all-grade diarrhea were 0.31 ( I2 = 51%, 95% CI: 0.14-0.69; P = .004) and .76 ( I2 = 65%, 95% CI: 0.62-0.93; P < .008) respectively, thus the use of intervention measures for preventing IID is effective, and the risk reduction of high-grade diarrhea was more significant. Subgroup analysis revealed that the monotherapy group (RR: 0.48, 95% CI: 0.21-1.13, I2 = 0%) and combination therapy group (RR: 0.14, 95% CI: 0.06-0.32, I2 = 0%) in the risk of high-grade diarrhea had no significant heterogeneity within the groups, and traditional herbal medicines (Kampo medicine Hangeshashin-to, PHY906 and hot ironing with Moxa Salt Packet on Tianshu and Shangjuxu) were effective preventive measures (RR:0.20, 95% CI: 0.07-0.60, I2 = 0%). The Jadad scores for traditional herbal medicines studies were 3, and the follow-up duration was only 2 to 6 weeks. Conclusion: This systematic review and meta-analysis suggest that preventive treatments significantly reduced the risk of high-grade and all-grade diarrhea, confirming the efficacy in the incidence and severity of IID, among which traditional herbal medicines (baicalin-containing) provided a protective effect in reducing the severity of IID. However, the traditional herbal medicines studies were of low quality. Combined irinotecan therapy can obtain better preventive effects than monotherapy of IID. These would be helpful for the prevention of IID in clinical practice.

2021-05-01·Chinese Journal of Natural Medicines

A four-component combination derived from Huang-Qin Decoction significantly enhances anticancer activity of irinotecan

Article

作者: Dai, Xiao-Min ; Hou, Xiao-Ying ; Wang, Ou ; Zhang, Zun-Jian ; Wang, Di ; Li, Dan-Ting ; Xu, Dou-Dou ; Lv, Bo ; Xu, Feng-Guo ; Qin, Si-Yuan ; Wan, Jian-Bo

Huang-Qin Decoction (HQD) is a classic prescription for diarrhea in Chinese medicine treatment. Recent studies have demonstrated that HQD and its modified formulation PHY906 could ameliorate irinotecan (CPT-11) induced gastrointestinal (GI) toxicity and enhance its anticancer therapeutic efficacy. Nevertheless, which constituents in HQD are effective is still unclear so far. The study aims to screen out the key bioactive components combination from HQD that could enhance the anticancer effect of CPT-11. First, the potential bioactive constituents were obtained through system pharmacology strategy. Then the bioactivity of each constituent was investigated synthetically from the aspects of NCM460 cell migration, TNF-α release of THP-1-derived macrophage and MTT assay in HCT116 cell. The contribution of each constituent in HQD was evaluated using the bioactive index E_i, which taken the content and bioactivity into comprehensive consideration. And then, the most contributing constituents were selected out to form a key-component combination. At last, the bioefficacy of the key-component combination was validated in vitro and in vivo. As a result, a key-component combination (HB4) consisting of four compounds baicalin, baicalein, glycyrrhizic acid and wogonin was screened out. In vitro assessment indicated that HB4 could enhance the effect of CPT-11 on inhibiting cell proliferation and inducing apoptosis in HCT116. Furthermore, the in vivo study confirmed that HB4 and HQD have similar pharmacological activity and could both enhance the antitumor effect of CPT-11 in HCT116 xenograft model. Meanwhile, HB4 could also reduce the CPT-11 induced GI toxicity.

项与 YIV-906 相关的新闻（医药）

2024-08-13

·drugs

Chinese Botanical Medicine Eases a Cancer Treatment Side Effect

TUESDAY, Aug. 12, 2024 -- An experimental drug based on ancient Chinese herbal medicine can help ease the toxic side effects of chemotherapy and radiation therapy in cancer patients, the results of a small new trial results suggest. A small group of 24 patients experienced fewer GI side effects from their treatment for rectal cancer after they took YIV-906, researchers reported recently in the Journal of Gastrointestinal Oncology . YIV-906 is based on an 1,800-year-old treatment for stomach ailments that combined licorice, dates, peonies and skullcap, researchers said. “This study is the first demonstration of YIV-906’s effectiveness in reducing GI toxicity caused by chemotherapy and radiation, showing the medicine’s potential of improving the patient’s quality of life while increasing treatment effectiveness,” said co-researcher Yung-Chi Cheng , a professor of pharmacology at Yale School of Medicine who helped develop the drug. For the four-year, phase 2 study, the patients were given capsules of YIV-906 along with chemo and radiation prior to surgery. At the time of surgery, about 17% of patients had a complete or near-complete response to their cancer treatment, while the overall survival rate at five years was 82%, results show. Only two cases of severe diarrhea were reported among the patients. YIV-906 is meant to ease side effects like diarrhea, fatigue and nausea. “We didn’t have any serious toxicity associated with the drug and patients found taking the drug in pill form very easy and tolerable,” senior researcher Dr. Susan Higgins , a professor of therapeutic radiology and of obstetrics, gynecology, and reproductive sciences at Yale. The results warrant further testing of YIV-906 in more patients with other types of cancer, such as pelvic cancer, researchers said in a Yale new release. People taking YIV-906 might be able to withstand harsher doses of both chemo and radiation therapy, making their cancer treatment more effective, the researchers added. Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.

临床结果放射疗法临床2期

2024-02-05

·GlobeNewswire-Health Care

Yiviva Announces Memorandum of Understanding with AstraZeneca to Develop Platforms, Technologies, and Innovative Therapeutics through a Systems Biology Approach

NEW YORK and SHANGHAI, China, Feb. 05, 2024 (GLOBE NEWSWIRE) -- Yiviva, a clinical-stage, platform biotechnology company developing systems biology medicines to treat aging-related diseases, signed a memorandum of understanding (MOU) with AstraZeneca China to establish a research and development collaboration at AstraZeneca’s Innovation Campus (iCampus) in Chengdu, China. The signing ceremony took place at the 2023 China International Import Expo (CIIE) at the National Exhibition and Convention Center in Shanghai. To address global unmet medical needs, Together Yiviva and AstraZeneca China will jointly build platforms for scientific research transformation and industrial development led by academicians and experts with the aim to modernize botanical medicines in accordance with new regulatory pathways for botanical medicines by the United States Food and Drug Administration (FDA) and China National Medical Products Administration (NMPA). “2023 marks the 30th anniversary of AstraZeneca in China. In collaboration with the Chengdu government and Chengdu High-Tech Industrial Zone (CDHT), AstraZeneca is establishing a modern healthcare development platform integrating traditional Chinese medicine and Western medicine. At CIIE, AstraZeneca announced plans to further globalize Chinese medicine. Our strategic partnership with Yiviva, will advance our blueprint for how to develop innovative medicines inspired by Chinese medicine,” remarked Lily Zhu, Vice President of AstraZeneca China and Head of DCI and CSE. “Disease knows no borders. By bringing together the knowledge and best practices of Western and Eastern Medicine, WE Medicine, we can learn from ancient wisdom to develop future medicines. Together with AstraZeneca China’s expertise, ecosystem, and resources, and Yiviva’s team, platform technologies, and pipeline, we can pioneer a new paradigm for systems biology drug development to address global unmet medical needs,” said Peikwen Cheng, Co-Founder and CEO of Yiviva. About Yiviva’s Platforms and Pipeline in Oncology Yiviva’s STAR (signal transduction, activity and response) drug discovery platform accelerates the identification of botanical therapeutics that influence immune function, inflammatory responses, cell growth, metabolic functions, and hormone activity. Through STAR, Yiviva can design sophisticated multi-target drugs that map to complicated disease biology. Yiviva has discovered six first-in-class drug candidates to treat cancer and inflammatory diseases. Yiviva applies patented, mechanism-based quality control linked to biological activity to manufacture batch-to-batch consistent drug product that satisfies established regulatory requirements for complex products. Yiviva’s lead candidate drug YIV-906 is a proprietary extract of 4 medicinal plants, inspired by an 1800-year-old traditional Chinese medicine formula. YIV-906 acts as an immunomodulator in the tumor microenvironment, turning cold tumors hot and potentiating anti-tumor activity for chemotherapies, immunotherapies, cell therapies, or radiation therapies; and acts as a cytoprotector in the gastrointestinal tract, reducing non-hematological toxicities and speeding up damaged tissue recovery. Yiviva has conducted 8 early-stage clinical trials in solid tumors (hepatocellular carcinoma, pancreatic cancer, colorectal cancer, and rectal cancers), with promising data suggesting that YIV-906 could prolong survival and improve quality of life. Yiviva recently recruited its last-patient-in in a first-line, randomized, double-blinded Phase 2b study of sorafenib plus YIV-906 in the treatment of hepatocellular carcinoma patients with hepatitis B. The CALM study is a multi-regional trial in the United States, Mainland China, Hong Kong, and Taiwan and expects a data readout in 2024. Yiviva recently published preclinical data conducted at Yale University about its novel therapeutic YIV-818-A to treat prostate cancer. YIV-818-A acts through multiple mechanisms, including androgen receptor downregulation, glucocorticoid receptor inhibition, epigenetic regulation and could help overcome drug resistance to prostate cancer and could enhance apalutamide, darolutamide, or enzalutamide efficacy. About Yiviva Yiviva is a clinical stage, platform biotechnology company developing systems biology medicines to prevent, treat, and/or cure aging-related diseases, including cancer and inflammatory diseases. The company was launched with Yale University and Henry Bronson Professor of Pharmacology and Medicine Yung-Chi Cheng as co-founders, with teams in the United States and Greater China. Yiviva’s investors include the National Foundation for Cancer Research and the Asian Fund for Cancer Research. For further information, please visit https://yiviva.com. About AstraZeneca AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialisation of prescription medicines in Oncology, Rare Diseases and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on social media @AstraZeneca. Contact:Email: hello@yiviva.com A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/8d78fdf0-e819-4a98-abe1-3944978b9ad8

临床2期免疫疗法

2021-04-30

·GlobeNewswire

Advanced Liver Cancer Drug Pipeline Prospers with an Inrush

Los Angeles, USA, April 29, 2021 (GLOBE NEWSWIRE) -- Advanced Liver Cancer Drug Pipeline Prospers with an Inrush of Pharma Companies and Emerging Novel Therapies A comprehensive analysis of 50+ key companies and 50+ emerging therapies enriching the Advanced Liver Cancer Pipeline Landscape. DelveInsight’s ‘Advanced Liver Cancer Pipeline Insights’ report provides a holistic view of the pipeline therapies that are under development in pre-clinical as well as clinical stages of development and growth prospects across the Advanced Liver Cancer domain. Some of the key highlights from the Advanced Liver Cancer pipeline report are: In the News Got queries? Want to know more? Request for Sample @ Advanced Liver Cancer Clinical Trial Analysis and Pipeline Insights Advanced Liver Cancer Pipeline Activity: At a Glance Reach out @ Advanced Liver Cancer Pipeline: Novel therapies and emerging technologies Advanced Liver Cancer Pipeline Agent Assessment The Advanced Liver Cancer Pipeline report lays down holistic coverage of active pipeline assets segmented by Stage, Product Type, Route of Administration, Molecule Type, Target, and Indications of various drugs. By Product Type By Stage By Molecule Type By Route of Administration By Mechanism of Action By Targets By Stage and Route of AdministrationBy Stage and Product Type For more information on emerging drugs, visit Advanced Liver Cancer Pipeline: Emerging Therapies and Trends Scope of the Report Coverage: GlobalKey Players: Siranomics, Novartis, Yiviva, Eisai, CAS Lamvac Biotech, Benhealth Biopharmaceutical, Chia Tai Tianqing Pharmaceutical, Surface Oncology, Zai Lab (Shanghai), Can-Fite Biopharma, Suzhou Zelgen Biopharmaceuticals, Innovent Biologics, SignalRX Pharmaceuticals, Carsgen Therapeutics, Shanghai Henlius Biotech, Jiangsu HengRui Medicine, Leap Therapeutics, Eureka Therapeutics, and many more.Key Advanced Liver Cancer Pipeline Therapies: STP 705, PDR001, YIV-906, H3B 6527, Plasmodium Immunotherapy, Activated CIK, AK105 Injection, SRF 388, MGD013, Namodenoson, SHR-1210, ET140203, PLM60, INC280, Donafenib, IBI308, SF1126, CAR-GPC3 T Cells, HLX10, and many more. Have a walkthrough of the report @ Advanced Liver Cancer Emerging Pipeline Key Questions Answered Need to clarify something? Get in touch @ Advanced Liver Cancer Drug Pipeline Insights Table of Contents Visit to know more of what’s covered @ Advanced Liver Cancer Emerging Therapies Other Insightful Reports Liver cancer IncidenceRead about the rising global burden of Liver Cancer. Excessive Daytime Sleepiness MarketGet a comprehensive analysis of epidemiology, pipeline therapies, and kye companies including Bioprojet Pharma/Harmony Biosciences, Axsome Therapeutics, Jazz Pharmaceuticals, BenevolentAI Bio, and many others. Bevacizumab Biosimilars InsightCoverage of about 40+ companies and 40+ marketed and pipeline drugs in Bevacizumab Biosimilars landscape. Pegfilgrastim Biosimilar InsightComprehensive insights about 20+ companies and 20+ marketed and pipeline drugs in Pegfilgrastim Biosimilars landscape. Different Types of Alternative MedicineKnow more about the state of Alternative Medicine in Healthcare and their changing landscape. Adeno-Associated Virus (AAV) Vectors in Gene TherapyAnalysis of emerging therapies and key companies including Pfizer (previously Sangamo Biosciences), NightstaRx Ltd, a Biogen Company, MeiraGTx, Neurocrine Biosciences/ Voyager Therapeutics, Roche (previously Spark Therapeutics)/Pfizer, Sangamo Therapeutics, Freeline Therapeutics, Spark Therapeutics, Asklepios Biopharmaceutical (Actus Therapeutics), Audentes Therapeutics, Roche/Sarepta Therapeutics, Horama S.A., MeiraGTx UK II Ltd, RegenxBio, Sangamo Therapeutics, Amicus Therapeutics, Amicus Therapeutics, and several others. Angelman Syndrome MedicationsA rich analysis of emerging drug therapies and key companies such as GeneTX Biotherapeutics, LLC, Ultragenyx Pharmaceutical Inc, Hoffmann-La Roche, Ovid Therapeutics Inc., Biogen, and others involved in the Angelman Syndrome market. Get in-depth knowledge of the healthcare and pharma world through DelveInsight's Competitive Intelligence Services and Business Solutions. About DelveInsight DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve. For more insights, visit Pharma, Healthcare, and Biotech News

基因疗法生物类似药免疫疗法

100 项与 YIV-906 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
晚期肝细胞癌	临床2期	中国	Yiviva, Inc.初创企业	2020-01-10
晚期肝细胞癌	临床2期	美国	Yiviva, Inc.初创企业	2020-01-10
晚期肝细胞癌	临床2期	中国台湾	Yiviva, Inc.初创企业	2020-01-10
结直肠癌	临床2期	美国	PhytoCeutica, Inc.	2002-02-01
腹泻	临床2期	美国	PhytoCeutica, Inc.	2002-02-01
转移性结直肠癌	临床前	美国	Kadmon Corp. LLC	2008-12-01
胰腺癌	临床前	美国	PhytoCeutica, Inc.	2006-12-01
胰腺癌	临床前	美国	Roche Pharma AG	2006-12-01
不可切除的肝细胞癌	临床前	美国	PhytoCeutica, Inc.	2003-10-01
不可切除的肝细胞癌	临床前	中国台湾	PhytoCeutica, Inc.	2003-10-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT00730158 (CTgov)	临床2期	转移性结直肠癌	33	Irinotecan+KD018 (Arm A - Irinotecan + KD018)	窪衊製鹹顧憲醖廠夢網(淵積壓窪鏇夢簾襯願鏇) = 膚艱鑰構構獵鹹繭膚製夢築鑰鹽選壓襯鏇鹹餘 (蓋鹹餘壓遞構構顧網網, 觸繭鹹憲蓋簾窪鑰淵鹹 ~ 淵艱糧鑰廠膚蓋範鏇艱) 更多	-	2019-05-22
				Placebo+Irinotecan (Arm B - Irinotecan + Placebo)	窪衊製鹹顧憲醖廠夢網(淵積壓窪鏇夢簾襯願鏇) = 顧願顧餘蓋簾願網淵積夢築鑰鹽選壓襯鏇鹹餘 (蓋鹹餘壓遞構構顧網網, 範衊願廠艱夢鏇淵淵獵 ~ 願窪醖鹹膚壓顧鹹衊願) 更多
NCT00411762 (CTgov)	临床1/2期	胰腺癌	25	Capecitabine+PHY906	(齋願窪網壓選網蓋簾觸) = 簾獵窪構簾獵憲繭膚製糧觸獵鏇鏇顧餘簾餘艱 (繭繭膚製觸築鑰餘築鏇, 餘憲選獵衊鏇積製壓餘 ~ 蓋鏇選鑰顧齋願淵願齋) 更多	-	2015-03-27
NCT04000737 (Pubmed \| Cancer Chemother Pharmacol)	临床2期	胰腺癌二线	25	Capecitabine + PHY906	(膚壓廠觸窪製糧構鹽鹽) = 鑰糧積範淵繭製願製積廠選艱蓋顧衊構範窪鏇 (憲範願鑰簾範繭鑰淵鏇 ) 更多	-	2014-02-01
ASCO2010	临床2期	胰腺癌	25	PHY906 plus capecitabine (CAP)	(積蓋憲膚蓋範願簾膚艱) = 齋選醖鹹醖簾壓衊窪構積願網製鹽憲簾簾膚衊 (製積鹹夢齋構鹹齋衊選 ) 更多	-	2010-05-20
NCT04000737 (Pubmed)	临床1/2期	晚期肝细胞癌	-	PHY906	(構繭鑰遞顧網襯製蓋憲) = 製鹹齋鏇衊築廠憲蓋獵壓簾淵齋積膚憲鑰壓鑰 (憲構觸糧憲選築膚廠壓 ) 更多	-	2009-10-01
ASCO2009	N/A	胃肠道肿瘤	44	PHY906	(餘觸淵壓夢壓築蓋願積) = 鹽艱蓋窪齋願積壓壓網衊齋糧構鬱齋獵憲壓構 (膚衊餘築積襯鏇齋餘夢 )	-	2009-05-20
				CAP alone	(餘觸淵壓夢壓築蓋願積) = 醖窪觸艱遞鏇糧範淵膚衊齋糧構鬱齋獵憲壓構 (膚衊餘築積襯鏇齋餘夢 )
ASCO2008	临床1/2期	肝细胞癌	-	Capecitabine	(憲顧窪糧願餘鹽糧積鹽) = 鏇醖選積淵壓築齋鏇鹽鑰製鹽廠選獵憲願窪憲 (觸鹹遞獵窪遞遞遞構壓 ) 更多	-	2008-05-20
				PHY906	(壓鹽獵餘廠選觸鬱製夢) = 餘壓壓願簾鏇鑰鑰築網醖憲繭餘鹹顧窪襯獵觸 (壓鏇壓壓鹽遞膚選膚餘 ) 更多
ASCO2007	临床1/2期	肝细胞癌	18	PHY906 + Capecitabine 1000 mg/m2 BID	憲膚獵壓憲顧網鏇鬱膚(繭網膚鑰窪醖艱願鹽齋) = 顧齋襯鏇糧餘選築願顧齋遞遞鬱壓構窪遞鑰網 (淵選繭餘糧遞艱醖顧膚 ) 更多	-	2007-06-20
				PHY906 + Capecitabine 750 mg/m2 BID	憲膚獵壓憲顧網鏇鬱膚(繭網膚鑰窪醖艱願鹽齋) = 夢築夢獵壓艱築獵願夢齋遞遞鬱壓構窪遞鑰網 (淵選繭餘糧遞艱醖顧膚 ) 更多